Phenobarbital

Quick links to important sections

Phenobarbital

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Phenobarbital

Quick Facts about Phenobarbital

Property Description
Active ingredient Phenobarbital (Phenobarbitone)
Form Tablets, oral solution, injection solution
Pharmacological class Barbiturate, Antiepileptic Drug (AED)
General purpose Seizure control, CNS stabilization
Origin Synthetic, derived from barbituric acid

What Type of Medicine is Phenobarbital?

Phenobarbital (also known as Phenobarbitone) is a prescription-only medication classified as a long-acting barbiturate and a primary Antiepileptic Drug (AED). This synthetic compound is derived chemically from barbituric acid and functions as a powerful Central Nervous System (CNS) depressant, reducing overall neurological excitability. Its efficacy in managing seizure disorders is widely clinically recognized, supported by pharmacological studies. As a classic agent for managing conditions involving hyperexcitable brain activity, it is a core medication listed as an Essential Medicine.


Composition and Available Forms of Phenobarbital

Phenobarbital is manufactured as a single-ingredient product (monotherapy), meaning the entire therapeutic effect comes solely from the active compound, Phenobarbital. It is unique among many AEDs for its established history of use across a wide patient group, including neonates and pediatric patients, where the oral solution form is often utilized. The medicine is supplied in several high-level dosage forms, including standard tablets, an oral solution (often with an aqueous or hydroalcoholic vehicle), and a sterile injection solution (parenteral formulation). This versatility ensures the drug can be administered orally for long-term control or via intramuscular or intravenous injection when rapid onset is critical.


What is the General Purpose of Phenobarbital?

The general purpose of Phenobarbital is to serve as an agent for seizure control by stabilizing brain function. It achieves this by acting powerfully on the central nervous system to dampen its activity, effectively slowing down the communication between nerve cells. The primary benefit is providing stability against recurrent, abnormal electrical activity in the brain, often observed in patients with epilepsy. It is recognized that Phenobarbital has a distinct action of depressing the sensory cortex and decreasing motor activity. This action helps ensure that nerve cells do not fire in an uncontrolled pattern, which is crucial for the prevention and control of electrical discharges.

Regulatory References

  1. Phenobarbital: MedlinePlus Drug Information
  2. Phenobarbital - Essential Medicines List
  3. PHENOBARBITAL tablet - DailyMed

What side effects are possible with Phenobarbital?

Possible Side Effects and Safety Information

The official safety documentation for Phenobarbital, a barbiturate antiepileptic drug, classifies adverse reactions based on the body systems affected and their frequency.

System-Organ Classes and Frequency

Adverse effects predominantly involve the Nervous System. The most Common adverse reaction is somnolence (drowsiness or sleepiness), along with related central nervous system depression, which is a recognized characteristic of the medicine. Other effects may involve Psychiatric Disorders (e.g., excitement, restlessness, anxiety) and Gastrointestinal Disorders (e.g., nausea, vomiting).

Classification System-Organ Class Examples
Common Nervous System (Somnolence, Confusion)
Rare Skin (Serious Dermatologic Reactions)
Other Respiratory, Hepato-biliary, Cardiac, Blood and Lymphatic System

Serious Adverse Reactions

The regulatory label identifies several rare but potentially life-threatening adverse reactions. These include severe cutaneous reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are sometimes fatal. Severe hepatotoxicity and profound respiratory depression are also documented serious risks. The labeling for all antiepileptic drugs includes the potential for increased risk of suicidal thoughts or behavior.

Safety Considerations for Specific Populations

Safety notes are provided for specific groups. In pediatric patients, particularly children under two years of age, there is a significantly higher risk of fatal hepatotoxicity. Older adults may react with marked confusion, depression, or paradoxical excitement. Furthermore, Phenobarbital is contraindicated in patients with a history of acute porphyria or marked hepatic impairment (severe liver dysfunction).

Exposure-Related Safety Patterns

The potential for physical dependence and withdrawal syndrome is a key safety pattern associated with chronic, long-term use. Serious hepatotoxicity has been noted to potentially occur during the first six months of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Phenobarbital overdose is classified as a medical emergency that can result in severe and potentially life-threatening outcomes, including death. The official regulatory profile is defined by pronounced central nervous system (CNS) depression and cardiovascular instability.

Documented Overdose Presentations

Manifestations of overdose are characterized by severe CNS depression, progressing from lethargy, slurred speech, and ataxia to stupor and deep coma. The most serious physiological signs involve the respiratory system, including shallow breathing and apnea, and the cardiovascular system, marked by profound hypotension and potential circulatory collapse. Other documented findings include hypothermia and areflexia.

Official labeling notes that elderly or debilitated patients may react with paradoxical excitement, and patients with hepatic or renal impairment face an increased risk of toxicity.

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose. Regulatory guidance explicitly mandates to contact emergency services (e.g., 911) if the patient is in a coma or experiencing severe difficulty breathing. Because no specific antidote is known, management focuses on symptomatic and supportive therapy. Officially described procedures include gastric lavage, administration of activated charcoal, and the use of dialysis to enhance drug removal in severe cases.

Therapeutic Uses of Phenobarbital

Phenobarbital may be part of symptomatic management in conditions involving sedative and anticonvulsant needs.


What Phenobarbital Treats: Main Uses and Benefits

Phenobarbital is commonly used across conditions characterized by periods of heightened symptoms related to seizure disorders. It is used to address seizure symptom clusters, including generalized tonic-clonic and specific partial manifestations. The primary therapeutic support involves assisting with maintaining functional stability to help prevent the recurrence of convulsive episodes, which contributes to easing the overall symptom load during routine activities.

The medication provides supportive relief when needed in acute clinical settings, playing a role in managing Status Epilepticus (a severe, continuous seizure manifestation). It is applied in addressing the challenging symptom burden associated with severe alcohol withdrawal syndromes, supporting patients during episodes of heightened discomfort. Additionally, Phenobarbital may assist with symptomatic relief from pronounced anxiety and apprehension where short-term support for heightened physiological activity is needed. The medicine is commonly used to help with neonatal seizures and for the prevention of recurrent febrile seizures in infants and young children, offering support that helps ease the overall symptom burden in conditions presenting with acute episodes.


Quick Fact: Relief for Neurological Hyper-excitability

Clinical Context Symptom Cluster Managed Patient Benefit
Chronic Epilepsy Convulsive Seizures (e.g., tonic-clonic) Helps maintain a sense of stability when symptoms are more noticeable.
Acute Settings Severe Neurological Distress/Withdrawal Supports the patient during difficult episodes by easing distress.
Pediatric Care Neonatal and Febrile Seizures Contributes to easing the overall symptom load in early life.

Regulatory References

  1. NIH DailyMed label

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Phenobarbital is a regulated drug whose use is defined by specific conditions and patient profiles outlined in government regulatory documents.

Eligibility Classification Populations
Absolute Contraindications Patients hypersensitive to barbiturates; those with manifest or latent acute intermittent porphyria; individuals with marked impairment of liver function or respiratory obstruction (dyspnea/obstruction is evident); and persons with a history of sedative/hypnotic addiction [Source 1.4].
Conditional or Restricted Use Patients with existing liver or renal impairment (where not severe); those with a history of drug dependence or abuse; and patients with suicidal ideation or emotional disturbances.
Age-Related Rules Use is established in neonates for certain seizures and in older children, but the drug is associated with a risk of cognitive deficits in pediatric patients [Source 1.4]. Older adults require caution, reduced dosage, and monitoring due to potential for heightened excitement or confusion [Source 1.2].
Pregnancy/Lactation Use is classified as high-risk (Category D for the injectable form) and is restricted to situations where the benefit warrants the potential fetal hazard. Caution is mandatory during lactation as the drug is excreted in breast milk [Source 3.1].

These official regulatory statements strictly define non-eligibility based on metabolic, organ function, and addiction risk, making use conditional or prohibited in vulnerable populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Phenobarbital is largely defined by its function as a strong inducer of hepatic microsomal enzymes, which accelerates the metabolism and elimination of numerous co-administered drugs. This pharmacokinetic effect can reduce the plasma concentration and efficacy of other medicines.

Documented Pharmacokinetic Interactions

Interacting Agents Official Interaction Outcome
Hormonal Contraceptives Decreased contraceptive effectiveness due to increased metabolism via enzyme induction.
Oral Anticoagulants (e.g., Warfarin) Decreased anticoagulant activity due to increased metabolic clearance.
Corticosteroids Reduced systemic effect due to enhanced metabolism.
Sodium Valproate / Valproic Acid Increased Phenobarbital plasma levels due to reduced Phenobarbital clearance.

Contraindicated and Pharmacodynamic Interactions

Co-administration with specific antiviral agents (e.g., Atazanavir, Doravirine) and antimalarials is contraindicated due to the risk of reduced therapeutic effect and loss of response. Combinations with CNS depressants, including alcohol and opioids, are documented to cause additive depressant effects, which include profound sedation.

Restrictions and Special Considerations

A mandatory timing separation is required for certain hormonal contraceptives (e.g., Dienogest/Estradiol Valerate), which must not be used for at least 28 days after discontinuing Phenobarbital. Administration is officially contraindicated in patients with marked impairment of liver function and in patients with a history of acute porphyrias.

Mechanism of Action

How Phenobarbital Works: Mechanism of Action


Enhanced Inhibitory Signaling at the GABA-A Receptor

Phenobarbital's primary mechanism involves acting as a positive allosteric modulator on the GABA-A receptor, which is the principal inhibitory receptor in the central nervous system (CNS). By binding to a specific site on this receptor complex, it prolongs the opening time of the associated chloride ion channel, thereby increasing the influx of chloride ions into the neuron.

Induction of Neuronal Hyperpolarization

This increased chloride influx causes neuronal hyperpolarization, a state where the cell's internal electrical charge becomes more negative. This core cellular event reduces neuronal excitability and influences the electrical properties of neural circuits, contributing to a change in activity within targeted pathways.

Central Nervous System Pathway Modulation

The resulting widespread increase in inhibition influences the level of activity across the central nervous system (CNS), resulting in a generalized CNS depressant effect. Furthermore, Phenobarbital may also influence excitatory pathways by possibly limiting the function of certain glutamate and calcium channels, influencing the activity of neural circuits or pathways that are highly active.

Dosage and Administration Information

Official Administration Routes and Dosing

Phenobarbital is administered via several officially approved routes, including oral administration for long-term use and intramuscular (IM) or slow intravenous (IV) injection primarily for acute care settings. The proper administration method is determined by the patient’s clinical need, with IV use reserved for close hospital supervision.

Usage Context Route Standard Dose Range (Adults) Frequency/Rate Constraint
Maintenance Therapy Oral (Tablet/Solution) 60 to 200 mg daily Once daily or in 2–3 divided doses
Acute Load Dose Intravenous (IV) 15 to 20 mg/kg Infusion rate must not exceed 60 mg per minute

Official Administration Guidelines and Special Considerations

Official labels detail precise instructions to ensure proper use. The oral formulations can generally be taken with or without food. For patients unable to swallow, tablets may be crushed and mixed with fluids or food, or an oral solution may be used.

When administered by injection, the lyophilized powder must be reconstituted prior to intravenous use. IV administration requires adherence to the maximum infusion rate to prevent issues related to rapid delivery. For long-term use, the total daily dosage must be carefully calculated and is subject to reduction in elderly or debilitated patients, as well as those with impaired hepatic or renal function. Discontinuation of Phenobarbital requires the dosage to be gradually reduced over a period of time to avoid adverse withdrawal effects.

Recent Clinical Evidence

Research evidence / Overview of studies for Phenobarbital

Phenobarbital was studied for several conditions characterized by fluctuating or episodic manifestations, with research focusing on how symptoms change over time. The available evidence, which includes regulatory data, focuses on the structure and findings of various types of trials and observational studies.


Evidence for Research Examining Acute Neurological Control in Neonates and Status Epilepticus

Short-term Randomized Controlled Trials (RCTs) and systematic reviews examined neonates, including both full-term and pre-term infants, for acute seizure control. Research also explored scenarios where the medicine was evaluated in second-line treatment protocols for Generalized Convulsive Status Epilepticus (GCSE). Data show patterns related to immediate cessation of seizure activity, but long-term outcomes regarding subsequent neurodevelopmental status are not well characterized. Sample sizes were modest in many comparison trials for GCSE, and follow-up durations were limited.


Evidence for Research Exploring Chronic Epilepsy in Children

RCTs and Observational Cohort Studies examined outcomes reflecting daily functioning, focusing on the frequency of convulsive seizure episodes and rates of seizure freedom over time. Findings describe patterns observed in the studies related to changes in seizure frequency. However, evidence quality varies across studies, particularly older trials, and comparative evidence is lacking in sufficient high-quality trials directly comparing this agent to all available newer antiepileptic drugs.


Evidence for Research Related to Acute Withdrawal Syndromes

The evidence base here was observed in Systematic Reviews, Meta-analyses, and Retrospective Cohort Studies for severe alcohol withdrawal syndrome (SAWS), monitoring physiological strain and time spent in the ICU/hospital. Studies report how symptoms evolved in the observed populations, describing patterns related to symptom resolution. Uniformity in dosing protocols across the various retrospective studies is often uncertain, and comparative evidence is lacking.


The Study Landscape for Research on Febrile Seizure Recurrence

RCTs explored outcomes related to physical discomfort, specifically tracking the prevention of seizure recurrence in young children. Findings indicate that the evidence for this use is limited, with studies reporting mixed results. Furthermore, long-term data describing patterns was associated with potential impacts on cognitive measures. Subgroup findings are uncertain, and certainty remains low for this application.


Long-Term Evidence and Maintenance of Stability

Research has explored the durability of response across conditions characterized by cycles of stability and flare-ups. Evidence suggests that long-term effects are not fully established or well-characterized across all outcomes. Data for certain groups remain insufficient, especially for comparative studies against newer agents or for very specific patient populations. Research remains ongoing in several areas to address these gaps.

Key Studies & References U.S. National Library of Medicine (NIH) DailyMed Drug Label for Phenobarbital

Frequently Asked Questions (FAQ)

Common questions about Phenobarbital (FAQ)

Q: Is Phenobarbital the same as phenobarbitone?

A: Yes, 'phenobarbitone' is an alternative name used in some regions for the substance most commonly referred to as Phenobarbital in official regulatory documents. They describe the same medicine.

Q: Can older adults use Phenobarbital safely?

A: Official information notes that dosage may require adjustment for elderly or debilitated patients. This is because older adults may be more likely to experience certain side effects, such as marked confusion, drowsiness, or depression. Any use in this population requires careful monitoring as described in official guidance.

Q: Do children react differently to Phenobarbital than adults?

A: Official safety data indicates that in pediatric patients, especially those under two years old, there is a noted higher risk for a severe liver reaction called fatal hepatotoxicity. Official information states that some children may also experience behavioral changes, such as hyperactivity or irritability.

Q: Is it possible to develop a dependency on Phenobarbital?

A: Yes, chronic, long-term use is associated with the potential for developing physical dependence and a withdrawal syndrome upon sudden cessation. Due to this potential for dependence and abuse, Phenobarbital is officially classified as a controlled substance.

Q: How should Phenobarbital be stopped when a person no longer needs it?

A: Official guidance states that to avoid adverse withdrawal effects, the dosage must be gradually reduced over a period of time. Official guidance emphasizes that any change to the routine, especially discontinuation, should be discussed with a healthcare professional.

Q: Can Phenobarbital be used by people with kidney problems?

A: The body eliminates the medicine more slowly in patients with impaired renal function (kidney problems). Official documents state that the total daily dosage may be subject to reduction due to the reduced elimination rate in patients with impaired renal function.

Q: How long does Phenobarbital stay in the body after the last dose?

A: Phenobarbital has a long elimination half-life, meaning it remains active in the body for an extended time. Official pharmacokinetic data shows that in adults, the average time for half of the substance to be cleared from the blood is approximately 79 hours (or about three days).

Q: What is the difference between Phenobarbital tablets and the liquid form?

A: Phenobarbital is officially available as both a tablet and an oral solution (liquid form). The oral solution allows for administration to individuals who are unable to swallow tablets, as noted in regulatory prescribing information.

Q: How quickly does Phenobarbital start working for seizures?

A: Official pharmacokinetic data indicates that the time it takes for the effects to begin can depend on the route of administration. Following oral intake, the onset of action is noted in official data to be approximately 30 to 60 minutes.

Q: Can Phenobarbital be used for anxiety or sleep issues?

A: While Phenobarbital is primarily indicated for treating various seizure types, official labels also state that it is sometimes used to provide sedation or to treat anxiety.

Q: Are there any long-term effects associated with using Phenobarbital?

A: Official information notes a risk of developing physical dependence and withdrawal syndrome with long-term use. Additionally, regulatory documents mention an association with the potential for megaloblastic anemia, which is a condition linked to deficiencies of folic acid and/or vitamin B12.

Q: What kind of routine blood tests are needed when taking Phenobarbital?

A: Official documents describe the need for monitoring the concentration of Phenobarbital in the blood. This process, known as therapeutic drug monitoring, is done to ensure levels remain within the approved range.

Q: Does Phenobarbital interact with common over-the-counter pain relievers?

A: Official labeling states that Phenobarbital may interact with certain over-the-counter pain relievers, such as acetaminophen. This interaction can alter the effects of the pain reliever by changing how quickly it is processed by the body.

Q: Can I drink coffee or caffeine while taking Phenobarbital?

A: Some authoritative sources indicate that caffeine may potentially increase the rate at which the body processes Phenobarbital. This could lead to lower levels of the medicine in the blood, potentially reducing its effect.

Q: Why is Phenobarbital sometimes used to treat withdrawal symptoms?

A: Phenobarbital is officially studied for and used in managing acute withdrawal syndromes, such as severe alcohol withdrawal syndrome. This is due to its documented central nervous system depressant and anti-seizure properties.

Q: How is Phenobarbital classified in terms of safety during pregnancy?

A: Regulatory documents officially describe Phenobarbital as a substance that may cause harm to the fetus when administered to a pregnant woman. Its use is associated with documented increased risks of major congenital malformations.

Q: What foods or supplements should be avoided while taking Phenobarbital?

A: Official documents explicitly advise against the use of alcohol while taking Phenobarbital. This is because combining the two can produce additive central nervous system depressant effects, including profound and dangerous sedation.

Q: Can I drive while I am taking Phenobarbital?

A: Official safety warnings state that Phenobarbital may cause somnolence (drowsiness) and generalized central nervous system depression. These effects could potentially impair the ability to perform skilled tasks such as driving or operating machinery.

Q: Is Phenobarbital a controlled substance?

A: Yes, Phenobarbital and its salts are subject to mandatory control under the Federal Controlled Substances Act in the United States. This classification is typically Schedule IV due to its potential for abuse and dependence.

Q: Does the effect of Phenobarbital wear off over time (tolerance)?

A: Official information notes that tolerance may develop to the sedative and hypnotic effects after repeated use. However, regulatory information notes that tolerance may not develop to all of its effects, such as those impacting breathing.

Q: How does taking alcohol affect Phenobarbital?

A: Official documents clearly state that the simultaneous use of alcohol and Phenobarbital can cause additive central nervous system depressant effects. This means the sedative effects are greatly increased, which can lead to profound sedation and be potentially dangerous.

Q: Why is Phenobarbital used to prevent fever-related seizures in children?

A: Studies have examined Phenobarbital's use for preventing the recurrence of febrile seizures. However, evidence for this application is described in research overviews as limited, with studies reporting mixed results.

Q: What studies have been conducted on Phenobarbital for neonatal seizures?

A: Official regulatory documents summarize research, including randomized controlled trials and systematic reviews, that examined its use for acute seizure control in term and pre-term infants.

Q: How does Phenobarbital compare to Primidone, which is related to it?

A: Primidone is a related anticonvulsant that is metabolized, or broken down, by the body into Phenobarbital, meaning Phenobarbital is one of its active components.

Q: Can Phenobarbital cause vitamin deficiencies?

A: Regulatory documents mention that long-term use is associated with the potential for megaloblastic anemia. This condition is linked to deficiencies of folic acid and/or vitamin B12.

Q: Is Phenobarbital suitable for individuals with a history of depression?

A: The official safety information for Phenobarbital, like all anti-epileptic drugs, includes a warning regarding the potential increased risk of suicidal thoughts or behavior. The official label notes that worsening of depression is listed as a possible adverse effect.

Q: Does Phenobarbital interact with herbal supplements like St. John's Wort?

A: Official sources note that St. John's Wort, an enzyme inducer, may potentially interact with Phenobarbital. This could increase the risk of certain side effects like dizziness and drowsiness.

Q: What are the main risks of taking Phenobarbital during breastfeeding?

A: Official safety documents indicate that Phenobarbital is present in human milk and can be passed to the infant. The primary risk noted is causing sedation in a breastfed infant, so caution is generally advised during lactation.

Q: Why does Phenobarbital need a prescription?

A: Phenobarbital requires a prescription because it is officially classified as a controlled substance. This classification is imposed by government regulation due to the medicine's potential for abuse, misuse, and physical dependence.

How should Phenobarbital be stored and disposed of?

How to Store and Dispose of Phenobarbital

Phenobarbital must be stored at Controlled Room Temperature, which is maintained between 20 C and 25 C (68 F and 77 F). The medicine must be protected from light and kept in a tightly closed, light-resistant container. Brief temperature excursions up to 30 C (86 F) are permitted. To prevent accidental ingestion, phenobarbital must always be stored out of the reach of children, often requiring a child-resistant closure upon dispensing.

For disposal, the FDA recommends taking unused or expired phenobarbital to an authorized drug take-back site. If a take-back option is not immediately available, Phenobarbital is one of the few medications listed by the FDA that may be disposed of by flushing it down the toilet to mitigate the risk of accidental exposure to others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Phenobarbital found in:

A-Z Index: